Overview
Cartalax is listed as a Khavinson bioregulatory tripeptide targeting cartilage and connective tissue, with molecular mass 333.29 g/mol and formula C12H19N3O8. It is part of the short-peptide bioregulator category, where very small sequences are proposed to influence gene-expression patterns in tissue-specific ways. In marketing, it is often positioned for joint health, cartilage maintenance, and aging connective tissue.
Cartilage biology is difficult. Chondrocytes live in a low-vascular extracellular matrix, and osteoarthritis involves mechanics, inflammation, aging, metabolism, and tissue breakdown. A short peptide that changes gene expression in a culture model would still need strong translational evidence before being described as cartilage repair in humans.
Cartalax is not FDA-approved for osteoarthritis, cartilage injury, joint pain, or connective-tissue repair. People with joint symptoms may need imaging, load management, physical therapy, anti-inflammatory strategies, weight reduction, injections, or surgery depending on the condition. Investigational bioregulators should not replace that workup.
This guide covers the proposed gene-regulatory mechanism, what is plausible in cartilage research, safety gaps, and how to keep expectations realistic when Cartalax is promoted alongside regenerative peptides such as BPC-157, TB-500, or GHK-Cu.
Quick facts
- Mechanism
- Short peptide bioregulator proposed to affect chondrocyte gene expression
- Primary use
- Cartilage Research
- Evidence
- limited
- FDA
- Not approved
- Route
- Oral or injectable research/bioregulator protocols
- Typical results
- Exploratory cartilage-cell signaling claims; no proven joint-regeneration outcome
Chemical information
Cartalax is listed as a short bioregulatory peptide with formula C12H19N3O8 and molecular mass 333.29 g/mol. Its small size distinguishes it from larger regenerative peptides, but also makes identity verification important.
How Cartalax works
Cartalax is proposed to act through the short-peptide bioregulator model, influencing gene-expression patterns linked to cartilage maintenance, extracellular matrix production, and chondrocyte survival. The hypothesis is mechanistically interesting, but it is not the same as demonstrated cartilage regrowth in people.
Chondrocytes regulate collagen II, aggrecan, proteoglycans, matrix metalloproteinases, and inflammatory mediators. A cartilage-targeted peptide would ideally reduce catabolic signaling while preserving normal matrix remodeling. Cartalax claims generally sit in this space, but modern independent trials with imaging endpoints such as MRI cartilage thickness or validated osteoarthritis scores are lacking.
The broader Khavinson literature proposes that short peptides can interact with DNA or chromatin and alter protein synthesis. That could theoretically affect tissue-specific repair programs, but tissue targeting, oral absorption, intracellular concentration, and sequence specificity need better confirmation for each peptide.
For practical users, Cartalax should be separated from pain relief. Even if a peptide affected chondrocyte signaling, joint pain may come from synovitis, bone marrow lesions, tendons, ligaments, meniscus, or nerve sensitization. A subjective pain change does not prove cartilage regeneration.
- Chondrocyte focus: Proposed to influence cartilage-cell maintenance signals
- Matrix hypothesis: Marketed around collagen and proteoglycan regulation
- Gene-expression model: Based on short-peptide bioregulator theory
- Low vascular target: Cartilage delivery is biologically challenging
- Evidence gap: No FDA-reviewed human cartilage-repair data
- Outcome caution: Pain relief does not prove structural cartilage change
Pharmacokinetics
Cartalax human PK is not established. Oral absorption, distribution to cartilage, half-life, and intracellular exposure are unknown, so claims about protocol timing or tissue targeting should be treated cautiously.
| Parameter | Value | Significance |
|---|---|---|
| Human PK | Not established | No validated half-life or cartilage exposure data |
| Route | Oral or injectable in market protocols | Route equivalence is unproven |
| Bioavailability | Unknown | Short peptides may be degraded or transported variably |
| Target tissue | Proposed cartilage/connective tissue | Cartilage delivery is difficult to verify |
| Metabolism | Peptidase degradation expected | Likely breakdown into amino acids and fragments |
| Structural outcomes | Not established | No reliable cartilage-thickness timeline exists |
Dosing & administration
There is no FDA-approved Cartalax dosing protocol. Commercial bioregulator cycles commonly use short courses, but these are not based on Western dose-ranging trials or validated joint-repair endpoints.
A responsible cartilage study would use objective baseline assessment, standardized exercise load, imaging or biomarker endpoints, pain and function scales, and adverse-event tracking. Without that, improvement may reflect rehab, rest, weight change, placebo effect, or natural fluctuation.
Cartalax should not be used to push through pain. Cartilage and connective-tissue injuries often worsen when loading exceeds tissue capacity, regardless of peptide use.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Cartalax has no robust human safety database. The main risks are unregulated sourcing, injectable contamination, overpromising cartilage regeneration, and delaying orthopedic or rheumatology evaluation.
Common
- • Injection site irritation
- • Mild stomach upset with oral products
- • Headache or fatigue reported anecdotally
- • No noticeable joint effect
- • Allergic reaction to excipients or impurities
- • Confusion with physical-therapy improvements
Serious / potential risks
- • Delayed diagnosis of structural joint injury
- • Contamination from injectable research products
- • Unknown effects in autoimmune arthritis
- • Unknown long-term safety in humans
- • Worsening activity due to overconfidence despite injury
Drug interactions
Formal interaction studies are unavailable; concerns are based on joint disease context and investigational immune or tissue effects.
| Medication | Interaction | Recommendation |
|---|---|---|
| NSAIDs | May mask pain and confound joint assessment | Track symptoms and avoid overloading injured joints |
| Corticosteroid injections | Could confound inflammation and pain outcomes | Separate interventions in research design |
| DMARDs or biologics | Unknown effects in autoimmune arthritis | Use only with rheumatology oversight |
| Anticoagulants | Injection bruising risk if injected | Avoid unsupervised injections |
| Other regenerative peptides | Stacking makes attribution impossible | Avoid multi-peptide claims without controls |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Bioregulator capsules | $40-$150 per cycle | Often sold as cartilage support courses |
| Research peptide vials | $50-$200+ | Identity and purity testing are important |
| Wellness programs | $200-$700+ | Frequently bundled with other peptides or therapies |
The bottom line
Cartalax is an investigational cartilage-focused bioregulator with limited independent support. It may be a research topic for chondrocyte signaling, but it should not be promoted as proven cartilage regeneration or used instead of proper joint care.
Best for
- • Chondrocyte gene-expression research
- • Reviews of Khavinson tissue-specific peptides
- • Exploratory studies with objective joint endpoints
Not for
- • Acute joint injury without diagnosis
- • Replacing physical therapy or orthopedic care
- • Autoimmune arthritis self-treatment
- • Expecting MRI-proven cartilage regrowth
Related compounds
Acetic Acid
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Amino Tadalafil
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
AOD-9604
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Astressin-B
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Frequently asked questions
References
- [1] Khavinson VK, Anisimov VN. Peptide regulation of aging: 35-year research experience. Bulletin of Experimental Biology and Medicine (2009). doi: 10.1007/s10517-009-0650-8 PMID: 19902107
- [2] Khavinson VK, Solovyov AY, Shataeva LK. Molecular mechanism of interaction between oligopeptides and double-stranded DNA. Bulletin of Experimental Biology and Medicine (2006). doi: 10.1007/s10517-006-0198-9 PMID: 17152370
- [3] Khavinson VK. Peptides, genome, aging. Advances in Gerontology (2014). PMID: 25306656
- [4] Linkova NS, Khavinson VK, Dyatlova AS. Peptide regulation of chondrogenic stem cell differentiation. Biology Bulletin Reviews (2023).
- [5] Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis & Rheumatism (2012). PMID: 22392533
- [6] Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Annals of the New York Academy of Sciences (2010). PMID: 20608920